The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2023

Filed:

Jul. 30, 2013
Applicants:

Kyoto Prefectural Public University Corporation, Kyoto, JP;

The Doshisha, Kyoto, JP;

Senju Pharmaceutical Co., Ltd., Osaka, JP;

Inventors:

Noriko Koizumi, Kyotanabe, JP;

Naoki Okumura, Kyotanabe, JP;

Shigeru Kinoshita, Kyoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 39/395 (2006.01); A61K 31/519 (2006.01); A61K 31/4725 (2006.01); A61K 31/4745 (2006.01); A61K 31/4709 (2006.01); A61K 31/4402 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 9/0048 (2013.01); A61K 31/4402 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/4745 (2013.01); A61K 31/519 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C12N 15/1136 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01);
Abstract

The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.


Find Patent Forward Citations

Loading…